Vivani Medical, Inc. (VANI)
- Previous Close
1.0300 - Open
1.0300 - Bid 0.7344 x 200
- Ask 1.3100 x 200
- Day's Range
1.0250 - 1.0400 - 52 Week Range
0.9050 - 2.0900 - Volume
20,363 - Avg. Volume
82,433 - Market Cap (intraday)
61.317M - Beta (5Y Monthly) 3.32
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4300 - Earnings Date May 13, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.00
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease and medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in clinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature and subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant for metabolic diseases in cats. The company is headquartered in Alameda, California.
www.vivani.comRecent News: VANI
View MorePerformance Overview: VANI
Trailing total returns as of 5/13/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VANI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VANI
View MoreValuation Measures
Market Cap
61.02M
Enterprise Value
61.98M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.47
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-35.31%
Return on Equity (ttm)
-122.42%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-23.49M
Diluted EPS (ttm)
-0.4300
Balance Sheet and Cash Flow
Total Cash (mrq)
18.35M
Total Debt/Equity (mrq)
109.67%
Levered Free Cash Flow (ttm)
-13.35M